October 9, 2018 / 5:08 AM / 7 days ago

BRIEF-Roche To Present New Data From Cancer Immunotherapy Programme at ESMO

Oct 9 (Reuters) - Roche Holding AG:

* ROCHE TO PRESENT NEW POSITIVE DATA FROM ITS BROAD CANCER IMMUNOTHERAPY PROGRAMME

* FIRST POSITIVE PHASE III STUDY RESULTS FOR A CANCER IMMUNOTHERAPY COMBINATION IN BREAST CANCER, WITH TECENTRIQ PLUS NAB-PACLITAXEL

* POSITIVE DATA FOR BOTH ALECENSA IN LUNG CANCER AND TECENTRIQ IN LUNG AND LIVER CANCERS

* NEW PIVOTAL RESULTS FROM TUMOUR-AGNOSTIC ENTRECTINIB STUDY ACROSS A BROAD RANGE OF CANCER TYPES FOR PEOPLE WHOSE TUMOURS HAVE BEEN IDENTIFIED AS NTRK GENE FUSION-POSITIVE Source text for Eikon: Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below